Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
US7521051B2 · kind B2 · utility
156Cited by
4References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 22, 2003 |
| Grant date | Apr 21, 2009 |
| Priority date | — |
| Expiry date | Dec 22, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.